Does the media refer more to LFVN or BNTC?

In the previous week, Lifevantage had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Benitec Biopharma. Lifevantage's average media sentiment score of 0.34 beat Benitec Biopharma's score of -0.54 indicating that Lifevantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer LFVN or GLSI?

In the previous week, Lifevantage and Lifevantage both had 3 articles in the media. Lifevantage's average media sentiment score of 0.34 beat Greenwich LifeSciences' score of -0.85 indicating that Lifevantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Which has stronger earnings & valuation, SNDL or LFVN?

Lifevantage has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $937.39M 0.40 -$11.29M -$0.03 N/A Lifevantage $228.53M 0.59 $9.81M $0.45 23.78

Is SNDL or LFVN more profitable?

Lifevantage has a net margin of 2.94% compared to SNDL's net margin of -1.19%. Lifevantage's return on equity of 23.89% beat SNDL's return on equity. Company Net Margins Return on Equity Return on Assets SNDL -1.19% -1.02% -0.85% Lifevantage 2.94% 23.89% 12.47%

Does the media refer more to SNDL or LFVN?

In the previous week, Lifevantage had 1 more articles in the media than SNDL. MarketBeat recorded 3 mentions for Lifevantage and 2 mentions for SNDL. Lifevantage's average media sentiment score of 0.34 beat SNDL's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SNDL 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IMRX or LFVN?

In the previous week, Lifevantage had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Lifevantage and 2 mentions for Immuneering. Lifevantage's average media sentiment score of 0.34 beat Immuneering's score of -0.30 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lifevantage (LFVN) Competitors

$10.70 +0.73 (+7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$10.74 +0.04 (+0.33%)

As of 07:13 PM Eastern

Compare

LFVN vs. BNTC, GLSI, ENTA, SNDL, and IMRX

Should you buy Lifevantage stock or one of its competitors? MarketBeat compares Lifevantage with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifevantage include Benitec Biopharma (BNTC), Greenwich LifeSciences (GLSI), Enanta Pharmaceuticals (ENTA), SNDL (SNDL), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Lifevantage compare to Benitec Biopharma?

Lifevantage (NASDAQ:LFVN) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Lifevantage presently has a consensus target price of $5.00, suggesting a potential downside of 53.27%. Benitec Biopharma has a consensus target price of $27.00, suggesting a potential upside of 157.14%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Lifevantage has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Lifevantage has a net margin of 2.94% compared to Benitec Biopharma's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Benitec Biopharma	N/A	-34.82%	-34.11%

Lifevantage has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lifevantage had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Benitec Biopharma. Lifevantage's average media sentiment score of 0.34 beat Benitec Biopharma's score of -0.54 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Lifevantage beats Benitec Biopharma on 11 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Greenwich LifeSciences?

Lifevantage (NASDAQ:LFVN) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Lifevantage has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifevantage currently has a consensus price target of $5.00, suggesting a potential downside of 53.27%. Greenwich LifeSciences has a consensus price target of $47.50, suggesting a potential upside of 119.40%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lifevantage has a net margin of 2.94% compared to Greenwich LifeSciences' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

In the previous week, Lifevantage and Lifevantage both had 3 articles in the media. Lifevantage's average media sentiment score of 0.34 beat Greenwich LifeSciences' score of -0.85 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Lifevantage has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

Lifevantage beats Greenwich LifeSciences on 9 of the 14 factors compared between the two stocks.

How does Lifevantage compare to Enanta Pharmaceuticals?

Lifevantage (NASDAQ:LFVN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Lifevantage has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

Lifevantage has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Lifevantage presently has a consensus price target of $5.00, indicating a potential downside of 53.27%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 83.25%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Lifevantage has a net margin of 2.94% compared to Enanta Pharmaceuticals' net margin of -89.56%. Lifevantage's return on equity of 23.89% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 22.0% of Lifevantage shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lifevantage had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Lifevantage and 0 mentions for Enanta Pharmaceuticals. Lifevantage's average media sentiment score of 0.34 beat Enanta Pharmaceuticals' score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Neutral
Enanta Pharmaceuticals	Neutral

Summary

Lifevantage beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lifevantage compare to SNDL?

SNDL (NASDAQ:SNDL) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Lifevantage had 1 more articles in the media than SNDL. MarketBeat recorded 3 mentions for Lifevantage and 2 mentions for SNDL. Lifevantage's average media sentiment score of 0.34 beat SNDL's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SNDL	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifevantage has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$937.39M	0.40	-$11.29M	-$0.03	N/A
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78

SNDL has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

35.3% of Lifevantage shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lifevantage has a net margin of 2.94% compared to SNDL's net margin of -1.19%. Lifevantage's return on equity of 23.89% beat SNDL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
Lifevantage	2.94%	23.89%	12.47%

SNDL currently has a consensus target price of $5.00, indicating a potential upside of 244.83%. Lifevantage has a consensus target price of $5.00, indicating a potential downside of 53.27%. Given SNDL's higher possible upside, equities research analysts plainly believe SNDL is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifevantage beats SNDL on 11 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Lifevantage had 1 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Lifevantage and 2 mentions for Immuneering. Lifevantage's average media sentiment score of 0.34 beat Immuneering's score of -0.30 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Lifevantage has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Lifevantage	$228.53M	0.59	$9.81M	$0.45	23.78

67.7% of Immuneering shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immuneering currently has a consensus target price of $16.50, suggesting a potential upside of 319.85%. Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 53.27%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifevantage has a net margin of 2.94% compared to Immuneering's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Lifevantage	2.94%	23.89%	12.47%

Summary

Lifevantage beats Immuneering on 10 of the 16 factors compared between the two stocks.

Get Lifevantage News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFVN vs. The Competition

Export

Metric	Lifevantage	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$135.03M	$15.66B	$6.43B	$12.05B
Dividend Yield	2.01%	1.16%	2.67%	5.56%
P/E Ratio	23.78	18.48	23.75	23.75
Price / Sales	0.59	2.20	480.27	84.51
Price / Cash	9.07	13.58	26.99	37.25
Price / Book	3.89	3.33	10.28	6.78
Net Income	$9.81M	$534.24M	$3.57B	$337.51M
7 Day Performance	13.47%	2.80%	-1.43%	-2.72%
1 Month Performance	100.37%	11.71%	3.27%	1.87%
1 Year Performance	-14.54%	0.15%	23.37%	26.61%

Lifevantage Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFVN Lifevantage	2.6193 of 5 stars	$10.70 +7.3%	$5.00 -53.3%	-20.4%	$135.03M	$228.53M	23.78	260	Gap Up High Trading Volume
BNTC Benitec Biopharma	1.4199 of 5 stars	$10.65 -7.8%	$27.00 +153.4%	-34.1%	$397.13M	N/A	N/A	20	News Coverage Gap Down
GLSI Greenwich LifeSciences	1.3559 of 5 stars	$23.72 -9.4%	$47.50 +100.3%	+130.3%	$395.01M	N/A	N/A	3	Upcoming Earnings Analyst Downgrade
ENTA Enanta Pharmaceuticals	1.7261 of 5 stars	$12.24 -7.0%	$20.29 +65.8%	+51.0%	$382.67M	$65.32M	N/A	160
SNDL SNDL	3.2111 of 5 stars	$1.46 -1.7%	$5.00 +243.6%	+7.6%	$375.80M	$937.39M	N/A	2,751

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFVN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifevantage (LFVN) Competitors

LFVN vs. BNTC, GLSI, ENTA, SNDL, and IMRX

How does Lifevantage compare to Benitec Biopharma?

Summary

How does Lifevantage compare to Greenwich LifeSciences?

Summary

How does Lifevantage compare to Enanta Pharmaceuticals?

Summary

How does Lifevantage compare to SNDL?

Summary

How does Lifevantage compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifevantage (LFVN) Competitors

LFVN vs. BNTC, GLSI, ENTA, SNDL, and IMRX

How does Lifevantage compare to Benitec Biopharma?

Do analysts prefer LFVN or BNTC?

Which has better valuation and earnings, LFVN or BNTC?

Is LFVN or BNTC more profitable?

Which has more volatility and risk, LFVN or BNTC?

Do institutionals & insiders hold more shares of LFVN or BNTC?

Does the media refer more to LFVN or BNTC?

Summary

How does Lifevantage compare to Greenwich LifeSciences?

Which has stronger earnings and valuation, LFVN or GLSI?

Do insiders & institutionals hold more shares of LFVN or GLSI?

Do analysts rate LFVN or GLSI?

Is LFVN or GLSI more profitable?

Does the media prefer LFVN or GLSI?

Which has more volatility and risk, LFVN or GLSI?

Summary

How does Lifevantage compare to Enanta Pharmaceuticals?

Which has preferable earnings and valuation, LFVN or ENTA?

Which has more risk & volatility, LFVN or ENTA?

Do analysts prefer LFVN or ENTA?

Is LFVN or ENTA more profitable?

Do institutionals & insiders believe in LFVN or ENTA?

Does the media refer more to LFVN or ENTA?

Summary

How does Lifevantage compare to SNDL?

Does the media refer more to SNDL or LFVN?

Which has stronger earnings & valuation, SNDL or LFVN?

Which has more volatility & risk, SNDL or LFVN?

Do insiders & institutionals believe in SNDL or LFVN?

Is SNDL or LFVN more profitable?

Do analysts prefer SNDL or LFVN?

Summary

How does Lifevantage compare to Immuneering?

Does the media refer more to IMRX or LFVN?

Which has more volatility & risk, IMRX or LFVN?

Which has preferable earnings & valuation, IMRX or LFVN?

Do insiders & institutionals have more ownership in IMRX or LFVN?

Do analysts rate IMRX or LFVN?

Is IMRX or LFVN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools